FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
NCT06564389
This study is recruiting at 5 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Healthy Participants
- Atopic Dermatitis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Pfizer
- Last updated on ClinicalTrials.gov
- July 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Anaheim Clinical Trials, LLC · Anaheim, CA
- TCR Medical Corporation · San Diego, CA
Florida · 1
- Miami Dermatology and Laser Research · Miami, FL
Michigan · 1
- Revival Research Institute, LLC · Troy, MI
Pennsylvania · 1
- Paddington Testing Company · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.